The Division of Pre-Clinical Innovation’s Therapeutics for Rare and Neglected Diseases (TRND) is part of the National Institutes for Health (NIH) National Center for Advancing Translational Sciences (NCATS). In the most recent U.S. budget passed by Congress, the NIH received a ‘down payment’ of $24 million to launch TRND. Subsequent funding is expected. A ‘rare […]
written on 12.03.2014